Glooko Highlights Inpatient Glycemic Safety Solution at 2026 Patient Safety Conference

According to a recent LinkedIn post from Glooko, the company is sponsoring the 2026 Mid-Atlantic Patient Safety Conference organized by the Mid-Atlantic Patient Safety Center. The post highlights a focus on inpatient glycemic safety through its EndoTool solution, developed by Monarch Medical Technologies, a Glooko company.

The LinkedIn post describes EndoTool as delivering advanced, patient-specific insulin dosing that adapts dynamically to evolving diabetes needs in hospital settings. This emphasis on technology-enabled glycemic management suggests Glooko is seeking deeper penetration in the inpatient diabetes care market and stronger alignment with hospital patient safety priorities.

For investors, the sponsorship may indicate ongoing commercial efforts to position EndoTool as a differentiated clinical decision support tool for hospitals, potentially supporting recurring enterprise contracts. Increased visibility at a regional patient safety conference could help expand Glooko’s provider network, though the post does not disclose any financial terms, adoption metrics, or revenue impact.

Strategically, the integration of Monarch Medical Technologies under the Glooko umbrella and the promotion of EndoTool reinforce the company’s broader move beyond outpatient data platforms into hospital-based care. If the solution can demonstrate measurable safety and efficiency benefits, it could enhance Glooko’s competitive position in the digital diabetes management and inpatient clinical software segments.